MMQ Stock Overview
A clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Mind Medicine (MindMed) Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.55 |
| 52 Week High | US$12.03 |
| 52 Week Low | US$2.67 |
| Beta | 2.33 |
| 11 Month Change | 33.75% |
| 3 Month Change | 39.30% |
| 1 Year Change | 182.98% |
| 33 Year Change | -70.91% |
| 5 Year Change | n/a |
| Change since IPO | 41.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| MMQ | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 3.1% | 1.4% | 0.8% |
| 1Y | 183.0% | -18.4% | 9.1% |
Return vs Industry: MMQ exceeded the German Pharmaceuticals industry which returned -19.3% over the past year.
Return vs Market: MMQ exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| MMQ volatility | |
|---|---|
| MMQ Average Weekly Movement | 12.7% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MMQ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: MMQ's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 57 | Rob Barrow | www.mindmed.co |
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Mind Medicine (MindMed) Inc. Fundamentals Summary
| MMQ fundamental statistics | |
|---|---|
| Market cap | €529.16m |
| Earnings (TTM) | -€93.35m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.7x
P/E RatioIs MMQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MMQ income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$97.80m |
| Earnings | -US$97.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.33 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 9.3% |
How did MMQ perform over the long term?
See historical performance and comparison